ICU Medical (ICUI) Stock Forecast & Price Target

ICU Medical is supported by a durable, recurring-revenue franchise in a structurally defensive infusion therapy market, with consumables, infusion systems, and vital care together delivering diversified demand and more than 60% of sales generated in the U.S., which helps underpin predictable mid-single-digit organic growth. The positive outlook is strengthened by recent operating execution, including 2Q revenue of $551.7M, adjusted EBITDA of $110M, and adjusted EPS of $2.37, alongside record results in consumables and infusion systems, 41.0% gross margin, 20.1% adjusted EBITDA margin, and raised FY2026 guidance to $415M-$435M of adjusted EBITDA and $8.60-$9.00 of adjusted EPS. Additional upside comes from the company’s improving financial profile, as $62M of free cash flow in 2Q and $50M of debt repayment reduced net leverage to 2.3x, while progress on the Medfusion 5000 FDA resubmission and ongoing margin expansion from tariffs, synergies, and operating leverage support further earnings and cash flow growth.

ICU Medical is facing a negative outlook because, despite a recent improvement in 2Q26 revenue growth to 6% from 1% in 1Q26, the business still appears dependent on incremental momentum in Consumables and Infusion Systems while Vital Care remains weak, with sales of $70M declining 4% and missing consensus. The operating picture is also clouded by product and execution risk, as management noted that some pump installations were pulled forward from 2H26 and that the Medfusion 5000 syringe pump still requires additional verification testing before the amended 510(k) is submitted later this year, limiting confidence in the durability of current growth. Even with raised 2026E and 2027E revenue and EPS estimates, the bear case still assumes revenue growth slows to the low-single digits with limited margin expansion and below-consensus earnings, underscoring concerns that the company’s improved top line may not translate into sustained fundamental improvement.